FcrR3A-158 Polymorphism and Stromal Tumor-Infiltrating Lymphocytes and Survival among Patients with Metastatic HER2-Positive Breast Cancer Receiving Trastuzumab-Based Treatment / 한국유방암학회지
Journal of Breast Cancer
;
: 45-50, 2018.
Article
in English
| WPRIM
| ID: wpr-713698
ABSTRACT
PURPOSE:
The prognosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has markedly improved since the introduction of trastuzumab. We aimed to evaluate the association between stromal tumor-infiltrating lymphocyte (sTIL) or FcrR polymorphisms and survival among patients with metastatic HER2-positive breast cancer who were treated with trastuzumab.METHODS:
A total of 56 women with recurrent or metastatic HER2-positive breast cancer who received the trastuzumab-taxane combination as first-line treatment were included in this retrospective analysis. The single-step multiplex allele-specific real-time polymerase chain reaction technique was employed for FcrR3A genotyping. sTILs were identified via immunohistochemical analysis of surgical (n=34, 60.7%) or biopsy specimens of metastatic lesions (n=22, 39.3%).RESULTS:
We classified patients based on the sTIL level (≤10% [n=44] or >10% [n=12]); high sTIL counts were more commonly observed in patients with hormone receptor-negative tumors than in those with hormone receptor-positive tumors (34.8% vs. 12.1%, p=0.02). There was a significant association between high sTIL levels and longer progression-free survival in comparison to low sTIL levels (median, 28.4 months vs. 16.8 months; p=0.03). With regard to the FcrR3A-158 genotype, patients were classified into the Phenylalanine/Phenylalanine group (23 patients, 41.1%), Phenylalanine/Valine group (23 patients, 41,1%), or Valine/Valine group (10 patients, 17.9%); these classifications were not associated with clinical outcomes.CONCLUSION:
High sTIL expression may be associated with better efficacy of trastuzumab-containing therapy in patients with metastatic HER2-positive breast cancer. However, this finding warrants further evaluation in the larger population.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Prognosis
/
Biopsy
/
Breast
/
Breast Neoplasms
/
Retrospective Studies
/
Lymphocytes, Tumor-Infiltrating
/
Classification
/
Receptor, ErbB-2
/
Disease-Free Survival
/
Real-Time Polymerase Chain Reaction
Type of study:
Observational study
/
Prognostic study
Limits:
Female
/
Humans
Language:
English
Journal:
Journal of Breast Cancer
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS